MENLO PARK, Calif., May 29, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced that it has filed a "shelf" registration statement with the Securities and Exchange Commission. This will replace the Company's previously filed shelf registration statement, which will expire in June 2012 and includes the registration for the sale of common stock, preferred stock or debt securities.
The Company currently has no plan to issue any securities under the registration statement, and the terms of any future offering pursuant to the registration statement would be established at the time of the offering.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state.
Depomed, Inc. is a specialty pharmaceutical company with two approved and marketed products. Gralise ® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.
CONTACT: August J. Moretti
|SOURCE Depomed, Inc.|
Copyright©2010 PR Newswire.
All rights reserved